Product Line Expansion: Halocarbon integrates metalworking fluids into its InfinX product line, providing greater convenience and flexibility for customers to directly order via the e-commerce platform, catering to diverse needs.
Compatibility Advantage: Three different formulations are compatible with standard minimum quantity lubrication (MQL) systems and most coolant delivery systems, ensuring seamless integration without major changes to tooling, setup, or operator training.
Performance Enhancement: The new fluids achieve 20X higher throughput, reduce cutting forces by 50%, extend tool life by 5X, and decrease surface roughness by 200%, significantly improving machining quality for high-temperature alloys and refractory metals.
Technological Innovation: Utilizing proprietary PCTFE-based technology, Halocarbon's metalworking fluids are non-flammable, non-hazardous, and chemically inert, ensuring exceptional performance in demanding industries while lowering tooling costs and enhancing production reliability.
HALO
$65.11+Infinity%1D
Analyst Views on HALO
Wall Street analysts forecast HALO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HALO is 77.63 USD with a low forecast of 56.00 USD and a high forecast of 92.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
Wall Street analysts forecast HALO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HALO is 77.63 USD with a low forecast of 56.00 USD and a high forecast of 92.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
3 Hold
0 Sell
Moderate Buy
Current: 65.770
Low
56.00
Averages
77.63
High
92.00
Current: 65.770
Low
56.00
Averages
77.63
High
92.00
Goldman Sachs
Neutral -> Sell
downgrade
$56
2025-12-04
Reason
Goldman Sachs
Price Target
$56
2025-12-04
downgrade
Neutral -> Sell
Reason
Goldman Sachs downgraded Halozyme to Sell from Neutral with a $56 price target. A central debate for Halozyme is the long-term value of its Enhanze royalty model, which faces a substantial post-2030 revenue cliff as roughly 70% of royalties roll off contract between 2030-2035 and appears unlikely to be offset through typical business-development pacing, the analyst tells investors in a research note. Current valuation implies a terminal value that assumes roughly $34B in new partner product revenue by 2041, a level that seems achievable only under optimistic scenarios despite the recent Elektrofi acquisition, the firm says.
Goldman Sachs
Neutral
maintain
$54 -> $56
2025-11-18
Reason
Goldman Sachs
Price Target
$54 -> $56
2025-11-18
maintain
Neutral
Reason
Goldman Sachs raised the firm's price target on Halozyme to $56 from $54 and keeps a Neutral rating on the shares. Halozyme announced a global non-exclusive collaboration and license agreement with Merus to use Halozyme's Enhanze technology in the development of a subcutaneous formulation of petosemtamab, the analyst tells investors in a research note. While strategically positive, Goldman doesn't expect the announcement to meaningfully move the stock.
Citizens JMP
Outperform
maintain
$91 -> $92
2025-11-04
Reason
Citizens JMP
Price Target
$91 -> $92
2025-11-04
maintain
Outperform
Reason
Citizens JMP raised the firm's price target on Halozyme to $92 from $91 and keeps an Outperform rating on the shares. Halozyme reported a strong quarter driven by indication and global expansion of ENHANZE partnered products, the analyst tells investors in a research note. The firm expects Halozyme to achieve 2026 EBITDA of more than $1B, a milestone it would reach a year ahead of prior long-term guidance.
JPMorgan
Jessica Fye
Neutral
maintain
$63 -> $65
2025-10-27
Reason
JPMorgan
Jessica Fye
Price Target
$63 -> $65
2025-10-27
maintain
Neutral
Reason
JPMorgan analyst Jessica Fye raised the firm's price target on Halozyme to $65 from $63 and keeps a Neutral rating on the shares. The firm updated the company's model ahead of the Q3 report.
About HALO
Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing solutions to improve patient experiences and outcomes for emerging and established therapies. The Company's commercially-validated solution, ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, is used to facilitate the subcutaneous delivery of injected drugs and fluids, with a focus on improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. The Company licenses its technology to biopharmaceutical companies to collaboratively develop products that combine ENHANZE with its partners’ proprietary compounds. It also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The Company has two commercial proprietary products, Hylenex and XYOSTED. It also has a proprietary ultra-high concentration microparticle formulation technology for biologics, branded Hypercon.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
